| Managing ocular allergy in the time of COVID-19 #MMPMID32402114Leonardi A; Fauquert JL; Doan S; Delgado L; Andant N; Klimek L; Bozkurt BAllergy 2020[Sep]; 75 (9): 2399-2402 PMID32402114show ga
ä|*Allergists[MESH]|*Ophthalmologists[MESH]|*Practice Patterns, Physicians'[MESH]|Administration, Ophthalmic[MESH]|Administration, Oral[MESH]|Adrenal Cortex Hormones/*therapeutic use[MESH]|Anti-Allergic Agents/therapeutic use[MESH]|Betacoronavirus[MESH]|COVID-19[MESH]|Calcineurin Inhibitors/*therapeutic use[MESH]|Conjunctivitis, Allergic/*drug therapy[MESH]|Coronavirus Infections/*epidemiology[MESH]|Disease Management[MESH]|Histamine Antagonists/*therapeutic use[MESH]|Humans[MESH]|Pandemics[MESH]|Pneumonia, Viral/*epidemiology[MESH]|Practice Guidelines as Topic[MESH]|Risk Assessment[MESH]|SARS-CoV-2[MESH]
DeepDyve Pubget Overpricing |
|